Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Castle Biosciences, Inc. (Nasdaq: CSTL) announced that CEO Derek Maetzold and CFO Frank Stokes will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. Eastern time. The presentation can be accessed via a live audio webcast on the company's website, with a replay available for two weeks afterward. Castle Biosciences focuses on innovative diagnostic tests for conditions like skin cancers and Barrett’s esophagus, aiming to improve patient care.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 21^st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 3:00 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma and Barrett’s esophagus. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq and TissueCypher are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005984/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When is Castle Biosciences' presentation at the Needham Virtual Healthcare Conference?

Castle Biosciences will present on April 12, 2022, at 3:00 p.m. Eastern time.

How can I access the Castle Biosciences webcast of the conference presentation?

The webcast can be accessed on Castle Biosciences' website during the conference.

What is the focus of Castle Biosciences' diagnostic tests?

Castle Biosciences focuses on tests for skin cancers, uveal melanoma, and Barrett’s esophagus.

What innovative tests is Castle Biosciences developing?

Castle Biosciences is developing a test to predict therapy response in patients with psoriasis and related conditions.

What is the stock symbol for Castle Biosciences?

The stock symbol for Castle Biosciences is CSTL.